HCG therapy in azoospermic men with lower or borderline testosterone levels and the prognostic value of Y‐deletion analysis in its outcome

Andrologia ◽  
2021 ◽  
Author(s):  
Syed Waseem Andrabi ◽  
Pallavi Saini ◽  
Meghali Joshi ◽  
Poonam Mehta ◽  
Girish Chandra Makker ◽  
...  
Keyword(s):  
Prognostic Value ◽  
Deletion Analysis ◽  
Testosterone Levels ◽  
Hcg Therapy

Prognostic value of total testosterone levels in patients with acute coronary syndromes

2019 ◽  
pp. 204748731985334
Author(s):  
Baris Gencer ◽  
Nicolas Vuilleumier ◽  
David Nanchen ◽  
Tinh-Hai Collet ◽  
Roland Klingenberg ◽  
...  
Keyword(s):  
Acute Coronary Syndromes ◽  
Prognostic Value ◽  
Total Testosterone ◽  
Testosterone Levels ◽  
Coronary Syndromes

Prognostic value of testosterone levels during chemotherapy with carboplatin plus weekly docetaxel in metastatic castration- and docetaxel-resistant prostate cancer (mDRPC).

2018 ◽  
Vol 36 (15_suppl) ◽  
pp. e17069-e17069
Author(s):  
Christoph W. Reuter ◽  
Philipp Ivanyi ◽  
Viktor Grünwald ◽  
Christoph AJ von Klot ◽  
Michael A. Morgan ◽  
...  
Keyword(s):  
Prostate Cancer ◽  
Prognostic Value ◽  
Testosterone Levels ◽  
Weekly Docetaxel

Prognostic value of Y deletion analysis

2001 ◽  
Vol 16 (1) ◽  
pp. 9-12 ◽  
Author(s):  
Swee Lian Liow ◽  
Eu Leong Yong ◽  
Soon Chye Ng
Keyword(s):  
Prognostic Value ◽  
Deletion Analysis

The prognostic value of nadir testosterone levels in prostate cancer patients treated with combined androgen blockade in Japanese men.

2015 ◽  
Vol 33 (15_suppl) ◽  
pp. e16049-e16049
Author(s):  
Shinichi Sakamoto ◽  
Shuhei Kamada ◽  
Koji Kawamura ◽  
Naoki Nihei ◽  
Takashi Imamoto ◽  
...  
Keyword(s):  
Prostate Cancer ◽  
Cancer Patients ◽  
Prognostic Value ◽  
Japanese Men ◽  
Testosterone Levels ◽  
Combined Androgen Blockade ◽  
Androgen Blockade

scholarly journals Changes in anthropometric characteristics, androgen and estrogen levels during correction of male hypogonadism with testosterone or hCG: results of a retrospective comparative study

2021 ◽  
Vol 18 (3) ◽  
pp. 268-275
Author(s):  
Z. S. Pavlova ◽  
I. I. Golodnikov ◽  
Y. A. Orlova ◽  
A. A. Kamalov
Keyword(s):  
Weight Loss ◽  
Total Sample ◽  
Total Weight ◽  
Sex Hormone Binding Globulin ◽  
Total Testosterone ◽  
Testosterone Replacement Therapy ◽  
Male Hypogonadism ◽  
Testosterone Levels ◽  
Hcg Therapy ◽  
Estradiol Levels

Background: The use of testosterone replacement therapy (TRT) is widespread. Despite the positive changes, such as: an increase in testosterone levels, an improvement in erectile function and an increase in libido, it is possible to develop a negative manifestation — hyperestrogenism. To date, there are no studies assessing the prevalence of hyperestrogenism in the presence of TRT.Aim: To study the reliability of an increase in total testosterone and estradiol levels and changes in total weight, body mass index (BMI), waist circumference (WC) and hips (OB), depending on the type of TRT and hCG therapy.Materials and methods: For retrospective analysis, the medical records of patients with baseline testosterone deficiency and normal estradiol levels, who were prescribed TRT or hCG therapy, were selected. The patients were divided into 3 groups depending on the form of TRT and hCG therapy. The level of testosterone, estradiol, sex hormone binding globulin (SHBG), weight, OT, OB, BMI in each group was assessed 2 times — before the appointment of treatment and at different periods of treatment, for example, after 3–6–9 and 12 months. Most of the patients had a period of monitoring these parameters before the appointment of TRT or hCG therapy and after 6 months.Results: The increase in the levels of total testosterone and estradiol against the background of TRT in the total sample was 109.6% and 111.3%, respectively. In each group, increases in total testosterone and estradiol levels were significant, p ≤ 0.001. The level of total testosterone to physiological values increased only in the 2-nd group — reaching the average-normal, recommended levels, from 8.7 ± 0.5 (2.5) to 16 ± 2 (10). The maximum rises in total testosterone, as well as estradiol, were noted in the 1st group, from 9.5 ± 0.72 nmol / L (3) to 24.9 ± 2.7 nmol / L (11.62)) and with 24.19 ± 2 (8.5) to 58.1 ± 4 (18.1), respectively. TRT, like hCG therapy, promotes an increase in the level of estradiol, which was demonstrated in all groups, and not only in group 1-st: in group 2-nd from 28.1 ± 2.3 (11.3) to 55 ± 4 (20) and in the 3-rd group from 27.1 ± 2.5 (10.5) to 55.8 ± 4.6 (19.6). On average for the entire sample, from 26.6 ± 1.32 (10.2) to 56.2 ± 2.5 (19). Weight loss on TRT was significant only in the 2-nd group, and in all parameters — weight, BMI, waist and hip circumference. In the 3-rd group, BMI, WC and OB values also slightly decreased. In the 1-st group, the total weight slightly increased, while the BMI did not change, as did the OB value, and the OT value decreased slightly.Conclusion: TRT significantly increases the levels of total testosterone and estradiol, contributing to the normalization of testosterone levels, as in the 2-nd group, or the development of supraphysiological levels of total testosterone and hyperestrogenism, as in the 1st and 3-rd groups. Given that there is a strong belief that TRT leads to significant weight loss, our study confirmed this statement only in the 2-nd group.

scholarly journals Prognostic value of testosterone for the castration-resistant prostate cancer patients: a systematic review and meta-analysis

2020 ◽  
Vol 25 (11) ◽  
pp. 1881-1891
Author(s):  
Noriyoshi Miura ◽  
Keiichiro Mori ◽  
Hadi Mostafaei ◽  
Fahad Quhal ◽  
Reza Sari Motlagh ◽  
...  
Keyword(s):  
Prostate Cancer ◽  
Systematic Review ◽  
Prognostic Value ◽  
Meta Analysis ◽  
Systemic Review ◽  
Castration Resistant Prostate Cancer ◽  
Poor Prognostic Factor ◽  
Testosterone Levels ◽  
Castration Resistant ◽  
Subgroup Analyses

Abstract Introduction This systematic review and meta-analysis aimed to assess the prognostic value of testosterone in patients with castration-resistant prostate cancer (CRPC). Materials and methods PubMed, Web of Science, and Scopus databases were systematically searched until December 2019, according to the Preferred Reporting Items for Systemic Review and Meta-analysis statement. The endpoints were progression-free survival (PFS) and overall survival (OS). Results We identified 11 articles with 4206 patients for systematic review and nine articles with 4136 patients for meta-analysis. Higher testosterone levels were significantly associated with better OS (pooled HR 0.74, 95% CI 0.58–0.95) and better PFS (pooled HR 0.51, 95% CI 0.30–0.87). Subgroup analyses based on the treatment type revealed that higher testosterone levels were significantly associated with better OS in CRPC patients treated with androgen receptor-targeted agents (ARTAs) (pooled HR 0.64, 95% CI 0.55–0.75), but not in those treated with chemotherapy (pooled HR 0.78, 95% CI 0.53–1.14). Conclusion This meta-analysis demonstrated that the PFS and OS were significantly greater in patients with CRPC in those with higher testosterone levels than that of those with lower testosterone levels. In the subgroup analyses, lower testosterone levels were a consistently poor prognostic factor for OS in patients treated with ARTAs, but not in those treated with chemotherapy. Therefore, higher testosterone levels could be a useful biomarker to identify patient subgroups in which ARTAs should be preferentially recommended in the CRPC setting.

scholarly journals Prognostic value of Y deletion analysis

2000 ◽  
Vol 15 (7) ◽  
pp. 1431-1434 ◽  
Author(s):  
Csilla Krausz ◽  
Lluis Quintana-Murci ◽  
Ken McElreavey
Keyword(s):  
Prognostic Value ◽  
Deletion Analysis
Sign in / Sign up

Export Citation Format

Share Document